Trials / Conditions / Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

12 registered clinical trials studyying Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Enrolling By Invitation	Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acu NCT06773936	SWOG Cancer Research Network	Phase 2
Not Yet Recruiting	Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world NCT07356960	Gruppo Italiano Malattie EMatologiche dell'Adulto	—
Not Yet Recruiting	Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Pos NCT07387926	Novartis Pharmaceuticals	Phase 1 / Phase 2
Recruiting	Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL NCT07250087	H. Lee Moffitt Cancer Center and Research Institute	Phase 1
Active Not Recruiting	Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diag NCT07074496	The First Affiliated Hospital of Soochow University	EARLY_Phase 1
Recruiting	Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and S NCT06061094	Goethe University	Phase 2
Completed	Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL NCT05594784	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Unknown	Iclusig PMS in CML or Ph+ALL Patients NCT03709017	Korea Otsuka Pharmaceutical Co., Ltd.	—
Completed	CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey NCT03647215	Incyte Biosciences UK	—
Completed	Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphobla NCT03678454	Incyte Biosciences Benelux	—
Completed	A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL NCT02081378	Novartis Pharmaceuticals	Phase 1
Completed	Rollover Study of BMS-354825 in Patients With CML and Ph+ALL NCT01030718	Bristol-Myers Squibb	Phase 1 / Phase 2